Title : Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.

Pub. Date : 2014

PMID : 25137071






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. Epirubicin microRNA 205 Homo sapiens
2 Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. Paclitaxel microRNA 205 Homo sapiens
3 CONCLUSIONS: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy. Epirubicin microRNA 205 Homo sapiens
4 CONCLUSIONS: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy. Paclitaxel microRNA 205 Homo sapiens